Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics, with a pipeline targeting oncology indications driven by key genetic alterations. The company went public in February 2022 through a de-SPAC merger with Panacea Acquisition Corp. II, a blank-check vehicle that completed its IPO in 2020 and was sponsored by Panacea Acquisition Management II LLC. Nuvation Bio filed an 8-K with the Securities and Exchange Commission on May 16, 2023, continuing its reporting obligations as a publicly traded entity in the biopharma sector. Sign up on SpacDesk for full filing history, deal analytics, and real-time data on Nuvation Bio and hundreds of other SPAC transactions.